The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): Assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND.
Christopher Michael Tully
No relevant relationships to disclose
Bernard H. Bochner
No relevant relationships to disclose
Guido Dalbagni
No relevant relationships to disclose
Emily C. Zabor
No relevant relationships to disclose
Harry W. Herr
No relevant relationships to disclose
S. Machele Donat
No relevant relationships to disclose
Irina Ostrovnaya
No relevant relationships to disclose
Ashley Marie Regazzi
No relevant relationships to disclose
Philip H. Kim
No relevant relationships to disclose
John P. Sfakianos
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Dean F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb; Lilly
Honoraria - Lilly